Table 1.
Monoclonal antibody-based clinical studies in myeloma.
| Target | Agent | Clinical Study Phase | Single Agent(S)/Combination(C) |
|---|---|---|---|
| Activin A | ACE-011 | I/II | S |
| BAFF | TabalumabL(mAb) | I/II | S, C (lenalidomide) |
| CD38 | Daratumumab | I | S |
| SAR650984 | I | S | |
| MOR202 | I | S | |
| CD40 | Dacetuzumab (SGN-40) | Ib | S, C (Lenalidomide) |
| Lucatumumab (HCD122) | I | S | |
| CD56 | huN901-DM1 (C-mAb) | I | S |
| CD74 | Milatuzumab | I/II | S |
| CD138 | BT062 (mAb-DM4) | I | S |
| CS1 | Elotuzumab | II/III | S,C(Lenalidomide, bortezomib) |
| CXCR3 | AMD3100 | II | C (bortezomib) |
| DKK-1 | BHQ-880 (mAb) | I/II | S |
| FGF, PDGF | TKI258(mAb) | I | S |
| HM1.24 | anti-HM1.24 (mAb) | ||
| IGF1/R | IGF1R CP-571 (mAb) | I | S |
| EM164 (mAb) | I | S | |
| IL6/R | Siltuximab (mAb) | II | S, C (bortezomib) |
| KIR | IPH101 (mAb) | I/II | S |
| MUC1 | AR20.5 (mAb) | I/II | S |
| RANKL | Denosumab (mAb) | I/II | S |
| TRAIL | Apo2L/TRAIL (Apo2 ligand) | I | S |
| Mapatumumab | I/II | S | |
| VEGF/R | Bevacizumab (mAb) | II | S |
| SU5416 | II | S | |
| Zactima (ZD6474) | II | S |